Elevation of
naphthoquinones and
estrogen quinones, which are reactive metabolites of
naphthalene and
estrogen, is thought to be an important
indicator of
naphthalene- and
estrogen-induced
carcinogenesis. We compared background levels of
naphthalene and
estrogen quinone-derived adducts in
serum albumin (Alb) from 143 women with
breast cancer and 119 healthy controls. Cysteinyl adducts of
naphthoquinones, including
1,2-naphthoquinone (1,2-NPQ) and
1,4-naphthoquinone (1,4-NPQ), and
estrogen quinones, including estrogen-2,3-quinones (E2-2,3-Q) and estrogen-3,4-quinones (E2-3,4-Q), were characterized after adduct cleavage. Levels of
estrogen quinones and
naphthoquinones were positively correlated in healthy controls, but not in
breast cancer patients (p < 0.05). Compared with controls, levels of 1,2-NPQ and
E2-3,4-Q were elevated by two- to ten-fold in
cancer patients (p < 0.001). To explore the correlation between
estrogen- and
naphthalene-derived
quinone adducts and disease status, we performed linear discriminant analysis of the ratio of 1,2-NPQ-Alb to (1,2-NPQ-Alb plus 1,4-NPQ-Alb) versus the ratio of E2-3,4-Q-2-S-Alb to (E2-2,3-Q-4-S-Alb plus E2-3,4-Q-2-S-Alb) in patients and controls. These two groups were separable using
albumin adducts of
estrogen quinones and
naphthoquinones, with 99.6% overall correct classification rate (overall accuracy). The findings of this study suggest that differences in the disposition of
estrogen and
naphthalene, and the subsequent elevation of cumulative
E2-3,4-Q and 1,2-NPQ may serve as
biomarkers of
breast cancer risk.